937 related articles for article (PubMed ID: 15477635)
41. Simulations model for predicting survival in women receiving adjuvant therapy for early breast cancer.
Ibrahim EM; Nassim FM; Ibrahm RE
Cancer J Sci Am; 1996; 2(4):234-40. PubMed ID: 9166538
[TBL] [Abstract][Full Text] [Related]
42. The choice of systemic adjuvant therapy in receptor-positive early breast cancer.
Dellapasqua S; Castiglione-Gertsch M
Eur J Cancer; 2005 Feb; 41(3):357-64. PubMed ID: 15691634
[TBL] [Abstract][Full Text] [Related]
43. Adjuvant hormone therapy for breast cancer: alternatives to tamoxifen.
Prescrire Int; 2005 Jun; 14(77):108-10. PubMed ID: 15984106
[TBL] [Abstract][Full Text] [Related]
44. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
[TBL] [Abstract][Full Text] [Related]
45. Ovarian ablation as adjuvant therapy for breast cancer.
Dees EC; Davidson NE
Semin Oncol; 2001 Aug; 28(4):322-31. PubMed ID: 11498826
[TBL] [Abstract][Full Text] [Related]
46. Management of premenopausal women with early-stage breast cancer: is there a role for ovarian suppression?
Baum M; O'Shaughnessy JA
Clin Breast Cancer; 2002 Oct; 3(4):260-7. PubMed ID: 12425754
[TBL] [Abstract][Full Text] [Related]
47. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
Mathew A; Davidson NE
Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
[TBL] [Abstract][Full Text] [Related]
48. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Goss PE
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
[TBL] [Abstract][Full Text] [Related]
49. Adjuvant endocrine therapy for postmenopausal women with early breast cancer.
Ingle JN
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1031s-1036s. PubMed ID: 16467121
[TBL] [Abstract][Full Text] [Related]
50. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
[TBL] [Abstract][Full Text] [Related]
51. [Chemotherapy and hormone therapy in breast carcinoma].
Jonat W; Eidtmann H
Praxis (Bern 1994); 1995 Mar; 84(13):386-9. PubMed ID: 7709119
[TBL] [Abstract][Full Text] [Related]
52. Prophylactic laparoscopic ovarian ablation for premenopausal breast cancer: medical and economic efficacy.
Kwon AH; Yamada O; Uetsuji S; Matsui Y; Kamiyama Y
Surg Laparosc Endosc; 1997 Jun; 7(3):223-7. PubMed ID: 9194283
[TBL] [Abstract][Full Text] [Related]
53. Adjuvant therapy of breast cancer.
Kaklamani VG; Gradishar WJ
Cancer Invest; 2005; 23(6):548-60. PubMed ID: 16203663
[TBL] [Abstract][Full Text] [Related]
54. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
Buzdar A; Chlebowski R; Cuzick J; Duffy S; Forbes J; Jonat W; Ravdin P
Curr Med Res Opin; 2006 Aug; 22(8):1575-85. PubMed ID: 16870082
[TBL] [Abstract][Full Text] [Related]
55. Re: Ovarian ablation or suppression in premenopausal early breast cancer: results from the International Adjuvant Breast Cancer Ovarian Ablation or Suppression randomized trial.
Ferretti G; Felici A; Carlini P; Cognetti F
J Natl Cancer Inst; 2007 Sep; 99(17):1344-5. PubMed ID: 17728217
[No Abstract] [Full Text] [Related]
56. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer.
Love RR; Duc NB; Allred DC; Binh NC; Dinh NV; Kha NN; Thuan TV; Mohsin SK; Roanh le D; Khang HX; Tran TL; Quy TT; Thuy NV; Thé PN; Cau TT; Tung ND; Huong DT; Quang le M; Hien NN; Thuong L; Shen TZ; Xin Y; Zhang Q; Havighurst TC; Yang YF; Hillner BE; DeMets DL
J Clin Oncol; 2002 May; 20(10):2559-66. PubMed ID: 12011136
[TBL] [Abstract][Full Text] [Related]
57. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.
Wheler J; Johnson M; Seidman A
Semin Oncol; 2006 Dec; 33(6):672-80. PubMed ID: 17145347
[TBL] [Abstract][Full Text] [Related]
58. DBCG trial 89B comparing adjuvant CMF and ovarian ablation: similar outcome for eligible but non-enrolled and randomized breast cancer patients.
Ejlertsen B; Jensen MB; Mouridsen HT; Andersen J; Cold S; Jakobsen E; Kamby C; Sørensen PG; Ewertz M
Acta Oncol; 2008; 47(4):709-17. PubMed ID: 18465339
[TBL] [Abstract][Full Text] [Related]
59. [Adjuvant tamoxifen duration: more large-scale randomized evidence is needed].
Davies C; Nomura Y; Ohashi Y
Gan To Kagaku Ryoho; 1997 Aug; 24(10):1203-9. PubMed ID: 9279337
[TBL] [Abstract][Full Text] [Related]
60. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]